Core Insights - The company, RIBON Instruments, reported that as of November 10, 2025, the number of shareholders is 23,486 [2] Company Summary - RIBON Instruments has engaged with investors through an interactive platform, providing updates on shareholder numbers [2] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [2]

Core Viewpoint - The company, RIBON Instrument (300206), announced the election of Mr. Xie Xicheng as the employee representative director of the sixth board of directors during the first meeting of the ninth employee representative assembly [1] Group 1 - The ninth employee representative assembly was recently held [1] - The employee representatives unanimously agreed to elect Mr. Xie Xicheng [1]

证券代码：300206 证券简称：理邦仪器 公告编号：2025-041 深圳市理邦精密仪器股份有限公司 二〇二五年十一月十三日 1 深圳市理邦精密仪器股份有限公司 关于选举产生第六届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 章程指引》等法律法规及《深圳市理邦精密仪器股份有限公司章程》（以下简称 "《公司章程》"）等有关规定，为保证深圳市理邦精密仪器股份有限公司（以 下简称"公司"）董事会的合规运作，公司于近日召开了第九届职工代表第一次 会议，经与会职工代表审议，一致同意选举谢锡城先生（简历见附件）担任公司 第六届董事会职工代表董事。 谢锡城先生由第六届董事会非职工代表董事变更为第六届董事会职工代表 董事，任期至第六届董事会任期届满之日止。本次选举完成后，公司董事会中兼 任高级管理人员职务的董事以及由职工代表担任的董事总计不超过公司董事总 数的二分之一。 特此公告。 深圳市理邦精密仪器股份有限公司 董事会 深圳市理邦精密仪器股份有限公司 附件： 第六届董事会职工代 ...

北京市中伦（深圳）律师事务所 关于深圳市理邦精密仪器股份有限公司 2025年第一次临时股东会的 法律意见书 致：深圳市理邦精密仪器股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股东会规则》 （下称"《股东会规则》"）等有关法律法规的规定及公司现行章程（下称"《公 司章程》"）的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受 深圳市理邦精密仪器股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年第一次临时股东会（下称"本次股东会"），并就本次股东会的召集和召 开程序、召集人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发 表法律意见。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料和口头证言均符合真实、准 确、完整的要求，有关副本、复印件等材料与原始材料一致。 法律意见书 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规及 《公司章程》的规定，以及出席、列席本次股东会人员的资格、召集人资格、会 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-040 深圳市理邦精密仪器股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、会议召开时间： 现场会议时间：2025 年 11 月 13 日（星期四）下午 15:00。 网络投票时间：2025 年 11 月 13 日；其中，通过深圳证券交易所交易系统 进行网络投票的具体时间为：2025 年 11 月 13 日上午 9:15-9:25、9:30-11:30，下 午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时间 为：2025 年 11 月 13 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：深圳市坪山区坑梓街道金沙社区金辉路 15 号理邦仪 器工业园会议室。 深圳市理邦精密仪器股份有限公司 6、会议的召集、召开与表决程序符合《公司法》《上市公 ...

Group 1 - The core point of the article is that the company, 理邦仪器 (Lepu Medical Technology), has disclosed that as of October 31, 2025, the number of its shareholders will be 24,365 [1]

Group 1 - The core point of the article is that the company, RIBON Instruments, reported its shareholder count as of October 31, 2025, which stands at 24,365 households [1]

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved total revenue of 1.45 billion CNY, a year-on-year increase of 5% [2] - The net profit attributable to shareholders reached 257 million CNY, showing a significant year-on-year growth of nearly 50% [2] - In Q3 2025, total revenue was 530 million CNY, representing a year-on-year increase of approximately 16% and a quarter-on-quarter increase of about 8% [3] Group 2: Market Performance - Domestic market revenue for the first three quarters was 530 million CNY, a decline of around 4% [2] - International market revenue reached 910 million CNY, with a year-on-year growth of 10.7%, contributing over 60% to total revenue [3] - In Q3 2025, domestic revenue was 176 million CNY, up 18% year-on-year, while international revenue was 357 million CNY, reflecting a growth of about 15% [3] Group 3: Strategic Initiatives - The company is collaborating with the Gates Foundation, receiving payments of 2.568 million USD and 1.547 million USD for project development [4] - Future plans include product upgrades and expanding local operations to maintain stable growth in overseas markets [3] Group 4: Contract Liabilities and R&D - Q3 contract liabilities increased significantly due to enhanced order acquisition capabilities, expected to convert into revenue and profit [5] - R&D expenses decreased while maintaining research intensity, attributed to the application of advanced technologies and efficient management practices [6][7] Group 5: Production and Sales Structure - The new facility in the U.S. spans 1,940 square meters and has received necessary certifications, focusing initially on monitoring and obstetric products [8] - The domestic sales structure includes 28 offices, ensuring comprehensive coverage and effective service support [9] - The international market employs a national agency sales model, with plans to establish subsidiaries in mature regions [10] Group 6: Product Performance - The i500 device, a key product, has shipped around 300 units and over 300,000 reagent units since the beginning of the year, supporting future growth in blood gas business [11] - The overall gross margin for the first three quarters was approximately 58%, with domestic gross margin at 64% and international gross margin at 55% [12]

Financial Performance - The company reported a revenue of 532.27 million yuan for the current period, representing a 15.72% increase compared to the same period last year [2] - Net profit attributable to shareholders increased by 118.28% to 102.17 million yuan, while the net profit excluding non-recurring items rose by 118.08% to 96.16 million yuan [2] - Basic and diluted earnings per share both reached 0.1763 yuan, marking a 118.15% increase [2] Non-Recurring Items - The company recorded a total of 6.02 million yuan in non-recurring gains for the current period, with government subsidies contributing 4.32 million yuan [3] - The total non-recurring gains for the year-to-date period amounted to 15.64 million yuan [3] Balance Sheet Changes - Accounts receivable increased by 61.22% to 235.31 million yuan, primarily due to increased sales to major customers [7] - Other current assets decreased by 70.72% to 1.46 million yuan, mainly due to the refund of prepaid income tax from the previous period [8] - Construction in progress rose by 35.70% to 162.84 million yuan, reflecting increased investment in the company's new facility [8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,710, with the top three shareholders holding significant stakes: Zhang Hao (21.05%), Zu Youdong (17.27%), and Xie Xicheng (17.18%) [21] Strategic Developments - The company is advancing its local manufacturing project in the U.S., having established a new facility in San Diego, which has received necessary certifications [24] - A collaboration with Global Health Labs, Inc. aims to develop an affordable handheld ultrasound device for low-income countries, with funding of 2.796 million USD allocated for the project [25][26] - The project has been further supported by a grant agreement with the Gates Foundation, providing an additional 2.65 million USD for clinical testing and market introduction [26]

Summary of the Conference Call for 理邦仪器 (Ribang Instrument) Company Overview - **Company**: 理邦仪器 (Ribang Instrument) - **Industry**: Medical Equipment Key Financial Performance - **Q3 2025 Revenue**: 530 million CNY, a year-on-year increase of approximately 16% and a quarter-on-quarter increase of about 8% [2][5] - **Net Profit**: 100 million CNY, a year-on-year increase of 118% and a quarter-on-quarter increase of approximately 14% [2][5] - **Domestic Market Revenue**: 176 million CNY, a year-on-year increase of 18% [2][5] - **International Market Revenue**: 357 million CNY, a year-on-year increase of approximately 15% [2][5] - **Patient Monitoring Line**: Achieved growth in both domestic and international markets [3][7] Growth Drivers - **Product Accumulation**: Strong foundation in product lines and enhanced competitiveness through AI and internet technology [6] - **International Market Investment**: Continuous investment since 2002 has yielded significant results, maintaining resilience despite uncertain trade environments [6] - **Manufacturing Capability**: Expansion of the U.S. base and FDA certification to enhance overseas sales capabilities [6][14] - **Internal Management**: Efficiency improvements and cost control through AI technology [6][13] Market Dynamics - **Domestic Demand**: Decrease in domestic demand in the maternal and child health sector, but significant growth in international markets [7] - **International Revenue Proportion**: Expected to be around 65% for 2025, with domestic revenue at approximately 35% [10] Future Outlook - **2026 Projections**: Anticipated continued double-digit growth in international markets, contingent on the international trade environment [10][20] - **Product Iteration and Localization**: Plans to enhance product competitiveness and optimize internal management [8] - **European Market Expansion**: Establishment of subsidiaries in France and Germany, with positive performance in the UK [9] Operational Insights - **Contract Liabilities**: Increased by 50% to over 10 million CNY, indicating strong operational status and competitive capability [4][12] - **Gross Margin**: Stable at 55%-60%, with an upward trend expected as new products are launched [4][19] - **Inventory Management**: Effective inventory management practices in manufacturing and sales, maintaining reasonable stock levels [18] Product Development - **A500 Product Launch**: New wet blood gas analysis device launched in 2025, with approximately 300 units sold and 400,000 tests conducted [17] - **Other Product Lines**: Continued growth in related devices, with strong market competitiveness [17] Conclusion - **Overall Performance**: The company has demonstrated robust growth in a challenging market environment, with a strong focus on international expansion and product innovation [3][20]